Gene Therapy for the Treatment of Primary Immune Deficiencies

Immune Deficiency and Dysregulation (DP Huston and C Kuo, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Immune Deficiency and Dysregulation

Abstract

The use of gene therapy in the treatment of primary immune deficiencies (PID) has advanced significantly in the last decade. Clinical trials for X-linked severe combined immunodeficiency, adenosine deaminase deficiency (ADA), chronic granulomatous disease, and Wiskott-Aldrich syndrome have demonstrated that gene transfer into hematopoietic stem cells and autologous transplant can result in clinical improvement and is curative for many patients. Unfortunately, early clinical trials were complicated by vector-related insertional mutagenic events for several diseases with the exception of ADA-deficiency SCID. These results prompted the current wave of clinical trials for primary immunodeficiency using alternative retro- or lenti-viral vector constructs that are self-inactivating, and they have shown clinical efficacy without leukemic events thus far. The field of gene therapy continues to progress, with improvements in viral vector profiles, stem cell culturing techniques, and site-specific genome editing platforms. The future of gene therapy is promising, and we are quickly moving towards a time when it will be a standard cellular therapy for many forms of PID.

Keywords

Gene therapy Primary immune deficiency Autologous bone marrow transplant Gene-modified hematopoietic stem cells 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Bousfiha A, Jeddane L, Al-Herz W, et al. The 2015 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2015;35:727–38. doi:10.1007/s10875-015-0198-5.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.••
    Pai S-Y, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. N Engl J Med. 2014;371(5):434–46. doi:10.1056/NEJMoa1401177. A major retrospective study of the factors influencing outcomes for patients with SCID treated by allogeneic transplant in multiple major centers across North America, highlighting the benefits of early diagnosis and treatment.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126(3):602–610.e11. doi:10.1016/j.jaci.2010.06.015.CrossRefPubMedGoogle Scholar
  4. 4.
    Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science. 1995;270(5235):475–80. doi:10.1126/science.270.5235.475.CrossRefPubMedGoogle Scholar
  5. 5.
    Chan B, Wara D, Bastian J, et al. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol. 2005;117(2):133–43. doi:10.1016/j.clim.2005.07.006.CrossRefPubMedGoogle Scholar
  6. 6.
    Serana F, Sottini A, Chiarini M, et al. The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency. J Immunol. 2010;185(12):7713–22. doi:10.4049/jimmunol.1001770.CrossRefPubMedGoogle Scholar
  7. 7.
    Gaspar HB, Aiuti A, Porta F, Candotti F, Hershfield MS, Notarangelo LD. How I treat ADA deficiency. Blood. 2009;114(17):3524–32. doi:10.1182/blood-2009-06-189209.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Onodera M, Ariga T, Kawamura N, et al. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood. 1998;91:30–6.PubMedGoogle Scholar
  9. 9.
    Kohn DB, Weinberg KI, Nolta JA, et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med. 1995;1(10):1017–23.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Bordignon C, Mavilio F, Ferrari G, et al. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID. Hum Gene Ther. 1993;4:513–20.CrossRefPubMedGoogle Scholar
  11. 11.
    Hoogerbrugge P, van Beusechem V, Fischer A, et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther. 1996;3(2):179–83.PubMedGoogle Scholar
  12. 12.••
    Aiuti A PhD, Cassani B, Callegaro L, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360(5):447–58. doi:10.1056/NEJMoa0805817. Report of the outcomes for the first 10 ADA-SCID patients treated by gene therapy using a gamma-retroviral vector and reduced intensity conditioning with a high rate of immune reconstitution.CrossRefPubMedGoogle Scholar
  13. 13.
    Gaspar HB, Buckland K, Rivat C, et al. Immunological and metabolic correction after lentiviral vector mediated haematopoietic stem cell gene therapy for ADA deficiency. Mol Ther. 2014;22(Supplement 1):S106.Google Scholar
  14. 14.
    Candotti F, Shaw KL, Muul L, et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency : clinical comparison of retroviral vectors and treatment plans. Blood. 2012;120(18):3635–46. doi:10.1182/blood-2012-02-400937.There.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Carbonaro Sarracino D, Shaw K, Sokolic R, et al. U.S. clinical gene therapy trials for adenosine deaminase-deficienct severe combined immune deficiency (ADA-SCID). J Clin Immunol. 2014;34(S2):139–515. doi:10.1007/s10875-014-0101-9.CrossRefGoogle Scholar
  16. 16.
    Aiuti A, Cassani B, Andolfi G, et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest. 2007;117(8):2233–40. doi:10.1172/JCI31666.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Pike-Overzet K, de Ridder D, Weerkamp F, et al. Gene therapy: is IL2RG oncogenic in T-cell development? Nature. 2006;443(7109):E5. doi:10.1038/nature05218. discussion E6-E7.CrossRefPubMedGoogle Scholar
  18. 18.
    Sokolic R, Maric I, Kesserwan C, et al. Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency. Blood. 2011;118(10):2688–94. doi:10.1182/blood-2011-01-329359.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Carbonaro Sarracino DA, Jin X, Wang X, et al. Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction. Blood. 2012;120(18):3677–87. doi:10.1182/blood-2012-02-408591.CrossRefGoogle Scholar
  20. 20.
    Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993;73(1):147–57. doi:10.1016/0092-8674(93)90167-O.CrossRefPubMedGoogle Scholar
  21. 21.••
    Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2010;363(4):355–64. doi:10.1056/NEJMoa1000164. Report of outcomes for subjects treated with a gamma-retroviral vector without any conditioning, leading to restoration of T cell immunity (although several developed T leukoprioliferative complications).CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004;364(9452):2181–7. doi:10.1016/S0140-6736(04)17590-9.CrossRefPubMedGoogle Scholar
  23. 23.
    Howe SJ, Mansour MR, Schwarzwaelder K, Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Investig. 2008;44(0):1–22. doi:10.1172/JCI35798DS1.
  24. 24.•
    Hacein-Bey Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132–42. doi:10.1172/JCI35700. A detailed and sophisticated molecular analysis of the mechanisms of insetrtional oncogenesis leading to T lymphoproliferation in XSCID subjects undergoing gene therapy with a "first generation" gamma-retroviral vector.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.••
    Hacein-Bey-Abina S, Pai S-Y, Gaspar HB, et al. A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency. N Engl J Med. 2014;371(15):1407–17. doi:10.1056/NEJMoa1404588. A recent report of successful restoration of T lymphocyte immunity without leukoproliferation or clonal expansions, using a "second generation: gamma-retroviral vector lacking strong enhancer elements.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    De Ravin SS, Gray JT, Throm RE, et al. False-positive HIV PCR test following ex vivo lentiviral gene transfer treatment of X-linked severe combined immunodeficiency vector. Mol Ther. 2014;22(2):244–5. doi:10.1038/mt.2013.296.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.•
    Seger RA, Gungor T, Belohradsky BH, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985–2000. Blood. 2002;100(13):4344–50. doi:10.1182/blood-2002-02-0583. A multi-center trial of reduced intensity conditioning for allogeneic transplant of Chronic Granulomatous Disease with excellent survival, even with unrelated donors.CrossRefPubMedGoogle Scholar
  28. 28.•
    Kang EM, Choi U, Theobald N, et al. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood. 2010;115(4):783–91. doi:10.1182/blood-2009-05-222760. This clinical trial of gene therapoy for CGD using a gamma-retroviral vector achieved only low level engraftment of gene corrected stem cells, yet still provided some benefit to subjects, providing proof-of-principle for this approach.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Notarangelo LD, Miao CH, Ochs HD. Wiskott-Aldrich syndrome. 2008.Google Scholar
  30. 30.
    Moratto D, Giliani S, Bonfim C, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an internationalcollaborative study. Blood. 2011;118(6):1675–85. doi:10.1182/blood-2010-11-319376.
  31. 31.
    Boztug K, Banerjee PP, Ph D, et al. Stem-cell gene therapy for the Wiskott-Aldrich Syndrome. N Engl J Med. 2010;363(20):1918–27.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for wiskott-Aldrich syndrome—long-term efficacy and genotoxicity. Sci Transl Med. 2014;6(227):1–14. doi:10.1126/scitranslmed.3007280.
  33. 33.•
    Hacein-Bey Abina S, Gaspar HB, Blondeau J, et al. Outcomes following gene therapy in patients with severe Wiskott-Aldrich Syndrome. JAMA. 2015;313(15):1550. doi:10.1001/jama.2015.3253. Successful restoration of immunity, with partial improvement in platelet counts, by gene therapy for Wiskott-Aldrich Syndrome using a lentiviral vector.CrossRefPubMedGoogle Scholar
  34. 34.•
    Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich Syndrome. Science. 2013;341(6148):1–12. doi:10.1126/science.1233151. Successful restoration of immunity, with partial improvement in platelet counts, by gene therapy for Wiskott-Aldrich Syndrome using a lentiviral vector.
  35. 35.
    Csaszar E, Kirouac DC, Yu M, et al. Rapid expansion of human hematopoietic stem cells by automated control of inhibitory feedback signaling. Cell Stem Cell. 2012;10(2):218–29. doi:10.1016/j.stem.2012.01.003.CrossRefPubMedGoogle Scholar
  36. 36.
    Pu J, Frescas D, Zhang B, Feng J. Utilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification. Exp Biol Med. 2015;240(8):1065–70. doi:10.1177/1535370215584932.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Division of Allergy, Immunology & Rheumatology, Department of PediatricsDavid Geffen School of Medicine at UCLALos AngelesUSA
  2. 2.Division of Hematology & Oncology, Department of PediatricsDavid Geffen School of Medicine at UCLALos AngelesUSA
  3. 3.Department of Microbiology, Immunology, and Molecular GeneticsUniversity of California Los AngelesLos AngelesUSA

Personalised recommendations